10 completed, 10 unknown, 7 recruiting, 3 not yet recruiting. 37 Phase 2, 11 Phase 1, 3 Phase 3.
Follow Relapse: new trials by email Literature Review of Relapse trials Research Report on Relapse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy Serplulimab, Second-Line Chemo/Targeted Therapy - Colorectal Cancer, Relapse | Phase 2 | Recruiting | Fudan University | 40 | 2026-05-10 | 2026-05-22 |
| Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma Epcoritamab, Loncastuximab Tesirine - Large B-cell Lymphoma, Relapse | Phase 2 | Recruiting | University of Miami | 26 | 2026-01-07 | 2026-10-15 |
| The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia Daratumumab - Aplastic Anemia, Refractory | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 37 | 2025-12-10 | 2025-12-17 |
| Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma IA Carboplatin + IA Caelyx, IA Carboplatin + IA Etoposide Phosphate - Glioblastoma Multiforme, Relapse | Phase 2 | Recruiting | Université de Sherbrooke | 120 | 2025-08-01 | 2025-08-07 |
| Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia BITE and DLI - Leukemia, Relapse | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 31 | 2025-08-01 | 2025-08-06 |
| Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention. Azacitidine (AZA) - Acute Myeloid Leukemia (AML), Relapse | Phase 2 | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 51 | 2025-01-16 | 2025-01-17 |
| Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention Azacitidine (AZA) Days 1 - 5, Decitabine (DAC), Venetoclax - T-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 59 | 2024-10-30 | 2025-05-07 |
| ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells Chemotherapy, Cell infusion - Hodgkin Lymphoma, Relapse | Phase 1 / Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 31 | 2024-04-25 | 2026-08-06 |
| Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion T-reg depleted DLI - Hematological Malignancies, Regulatory T Cell Depletion | Phase 1 / Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 27 | 2024-03-01 | 2024-02-14 |
| Isa-Pom-Dex in Elderly/Frail Subjects With RRMM Isatuximab, Pomalidomide, Dexamethasone - Multiple Myeloma, Relapse | Phase 2 | Active not recruiting | UNC Lineberger Comprehensive Cancer Center | 6 | 2023-12-05 | 2026-06-09 |
| Primaquine Double Dose for Radical Cure of Plasmodium Vivax in Colombia Primaquine double dose over 14 days, Primaquine single dose over 14 days - Malaria, Vivax, Relapse | Phase 2 / Phase 3 | Withdrawn | University of California, San Francisco | 2023-01-20 | 2023-05-11 | |
| PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma PD-1 inhibitor - Hodgkin Lymphoma, Adult, Relapse | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 47 | 2022-01-01 | 2021-12-17 |
| Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies Ibrutinib Combined With Rituximab - DLBCL, MYD88 Gene Mutation | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 20 | 2021-10-01 | 2021-08-06 |
| Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute Leukemia Sorafenib - Acute Leukemia, Relapse | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 346 | 2020-12-15 | 2021-11-08 |
| Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia Dual target CAR-T cell therapy - Dual-target CAR-T Cells, B ALL | Phase 1 / Phase 2 | Unknown | Shenzhen University General Hospital | 20 | 2020-10-20 | 2021-01-26 |
| HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis Treatment Arm - high dose ATG, Control Arm - standard of care - Graft-versus-host-disease, Relapse | Phase 2 | Terminated | AHS Cancer Control Alberta | 68 | 2020-07-01 | 2025-07-18 |
| Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM Daratumumab, Carfilzomib, Pomalidomide - Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Active not recruiting | Andrew Yee, MD | 44 | 2020-05-18 | 2026-10-15 |
| Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse Bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination - Epithelial Ovarian Cancer, Relapse | Phase 2 | Unknown | ARCAGY/ GINECO GROUP | 74 | 2019-03-01 | 2022-08-17 |
| Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies Prophylactic DLI - Donor Lymphocyte Infusion, Peripheral Blood Stem Cell Transplantation | Phase 2 | Unknown | Chinese PLA General Hospital | 40 | 2019-01-01 | 2018-12-13 |
| IA Carboplatin + Radiotherapy in Relapsing GBM IA Carbo+ Radiation - Glioblastoma Multiforme, Relapse | Phase 1 / Phase 2 | Recruiting | Université de Sherbrooke | 35 | 2018-07-10 | 2025-08-11 |
Showing 20 of 37. Sign in to see all of them.
Recurrence (37) · Graft vs Host Disease (5) · Multiple Myeloma (5) · Hematologic Neoplasms (3) · Leukemia (3) · Lymphoma (3) · Anemia, Aplastic (2) · Glioblastoma (2) · Hodgkin Disease (2) · Neoplasm, Residual (2) · Anxiety Disorders (1) · Burkitt Lymphoma (1) · Carcinoma, Ovarian Epithelial (1) · Colorectal Neoplasms (1) · Dendritic Cell Sarcoma, Interdigitating (1)
Disease Attributes (37) · Pathologic Processes (37) · Pathological Conditions, Signs and Symptoms (37) · Neoplasms (26) · Hemic and Lymphatic Diseases (20) · Neoplasms by Histologic Type (19) · Immune System Diseases (17) · Hematologic Diseases (14) · Immunoproliferative Disorders (13) · Lymphoproliferative Disorders (13) · Lymphatic Diseases (9) · Neoplasms by Site (7) · Blood Protein Disorders (5) · Cardiovascular Diseases (5) · Hemorrhagic Disorders (5)
Decitabine (3) · Azacitidine (2) · Dexamethasone (2) · Drug Therapy (2) · Lenalidomide (2) · Rituximab (2) · carfilzomib (2) · daratumumab (2) · pomalidomide (2) · Bevacizumab (1) · Bortezomib (1) · Carvedilol (1) · Cord Blood Stem Cell Transplantation (1) · Dental Occlusion (1) · Immune Checkpoint Inhibitors (1)
Assistance Publique - Hôpitaux de Paris (3) · Chinese PLA General Hospital (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Nanfang Hospital, Southern Medical University (2) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2) · UNC Lineberger Comprehensive Cancer Center (2) · Université de Sherbrooke (2) · AHS Cancer Control Alberta (1) · ARCAGY/ GINECO GROUP (1) · Aaron J. Janowsky (1) · Andrew Yee, MD (1) · Centre Francois Baclesse (1) · Centre Henri Becquerel (1) · Chinese Academy of Medical Sciences (1) · First Affiliated Hospital of Zhejiang University (1)
China (13) · United States (7) · France (6) · Canada (3) · Belgium (1) · Germany (1) · Russia (1)
David Fortin, MD (2) · Qifa Liu (2) · Andrew J Yee, MD (1) · Attaphol Pawarode, M.D. (1) · David Mischoulon, M.D. (1) · Dehui Zou, Dr. (1) · Eben I Lichtman, MD (1) · Elena Parovichnikova, Prof MD PhD (1) · Gilles Freyer (1) · JIong HU, M.D. (1) · Jan Storek, MD (1) · Juan Alderuccio, MD (1)
PMID 19182205, PMID 19534336, PMID 19760366, PMID 20650872, PMID 22242033, PMID 22284691, PMID 22931705, PMID 23844725, PMID 24026531, PMID 24947313, PMID 27736689, PMID 29760162, PMID 30698644, PMID 32164760, PMID 32873343, PMID 33235353, PMID 35467818, PMID 36105799, PMID 36372356
P50DA018165 (1)